Approval · Notice of Compliance 37975 · 2026
JAKAVI: Notice of Compliance 37975
Issued July 23, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37975
- Date
- July 23, 2026
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a manufacturing site and manufacturer involving production of the starting material. Addition of a manufacturing site and manufacturer involving production of the drug substance. Change in the manufacturing process for the drug substance
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAKAVI | Not yet assigned | — |
Medicinal ingredients
- RUXOLITINIB PHOSPHATE 5 MG per TAB
- RUXOLITINIB PHOSPHATE 10 MG per TAB
- RUXOLITINIB PHOSPHATE 15 MG per TAB
- RUXOLITINIB PHOSPHATE 20 MG per TAB